Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia

Diego Novick,1 William Montgomery,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Gang Zhu,4 Li Yue,5 Jihyung Hong,6 Héctor Dueñas,7 Roberto Brugnoli8 1Eli Lilly and Company, Windlesham, Surrey, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 3Parc Sanitari Sant Joan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Novick D, Montgomery W, Haro JM, Moneta MV, Zhu G, Yue L, Hong J, Dueñas H, Brugnoli R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Depression Antidepressant Duloxetine SSRI Functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/817d96775c9744fba77c329c4524847d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:817d96775c9744fba77c329c4524847d
record_format	dspace
spelling	oai:doaj.org-article:817d96775c9744fba77c329c4524847d2021-12-02T02:40:30ZFunctioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia1178-2021https://doaj.org/article/817d96775c9744fba77c329c4524847d2016-02-01T00:00:00Zhttps://www.dovepress.com/functioning-in-patients-with-major-depression-treated-with-duloxetine--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Diego Novick,1 William Montgomery,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Gang Zhu,4 Li Yue,5 Jihyung Hong,6 Héctor Dueñas,7 Roberto Brugnoli8 1Eli Lilly and Company, Windlesham, Surrey, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 3Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; 4Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, 5Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 6Department of Healthcare Management, Gachon University, Seongnam, South Korea; 7Eli Lilly de Mexico, Mexico City, Mexico; 8School of Medicine, Sapienza University of Rome, Rome, ItalyPurpose: To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of ≤60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments.Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 patients with major depressive disorder without sexual dysfunction. The present analysis focused on a subgroup of patients from East Asia (n=587). Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS were rated using the modified Somatic Symptom Inventory. A mixed model with repeated measures was fitted to compare the levels of functioning between duloxetine-treated (n=227) and SSRI-treated (n=225) patients, adjusting for baseline patient characteristics.Results: The mean SDS total score was similar between the two treatment cohorts (15.46 [standard deviation =6.11] in the duloxetine cohort and 16.36 [standard deviation =6.53] in the SSRI cohort, P=0.077) at baseline. Both descriptive and regression analyses confirmed improvement in functioning in both groups during follow-up, but duloxetine-treated patients achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard error =0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better functioning) than that of 6.76 (standard error =0.77) in the SSRI cohort (P<0.001). This treatment difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns were also observed for SDS subscores (work, social life, and family life).Conclusion: Depressed patients treated with duloxetine achieved better functioning compared to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS at baseline.Keywords: depression, antidepressant, duloxetine, SSRI, functioningNovick DMontgomery WHaro JMMoneta MVZhu GYue LHong JDueñas HBrugnoli RDove Medical PressarticleDepressionAntidepressantDuloxetineSSRIFunctioningNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 383-392 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Depression Antidepressant Duloxetine SSRI Functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Depression Antidepressant Duloxetine SSRI Functioning Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Novick D Montgomery W Haro JM Moneta MV Zhu G Yue L Hong J Dueñas H Brugnoli R Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
description	Diego Novick,1 William Montgomery,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Gang Zhu,4 Li Yue,5 Jihyung Hong,6 Héctor Dueñas,7 Roberto Brugnoli8 1Eli Lilly and Company, Windlesham, Surrey, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 3Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; 4Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, 5Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 6Department of Healthcare Management, Gachon University, Seongnam, South Korea; 7Eli Lilly de Mexico, Mexico City, Mexico; 8School of Medicine, Sapienza University of Rome, Rome, ItalyPurpose: To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of ≤60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments.Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 patients with major depressive disorder without sexual dysfunction. The present analysis focused on a subgroup of patients from East Asia (n=587). Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS were rated using the modified Somatic Symptom Inventory. A mixed model with repeated measures was fitted to compare the levels of functioning between duloxetine-treated (n=227) and SSRI-treated (n=225) patients, adjusting for baseline patient characteristics.Results: The mean SDS total score was similar between the two treatment cohorts (15.46 [standard deviation =6.11] in the duloxetine cohort and 16.36 [standard deviation =6.53] in the SSRI cohort, P=0.077) at baseline. Both descriptive and regression analyses confirmed improvement in functioning in both groups during follow-up, but duloxetine-treated patients achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard error =0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better functioning) than that of 6.76 (standard error =0.77) in the SSRI cohort (P<0.001). This treatment difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns were also observed for SDS subscores (work, social life, and family life).Conclusion: Depressed patients treated with duloxetine achieved better functioning compared to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS at baseline.Keywords: depression, antidepressant, duloxetine, SSRI, functioning
format	article
author	Novick D Montgomery W Haro JM Moneta MV Zhu G Yue L Hong J Dueñas H Brugnoli R
author_facet	Novick D Montgomery W Haro JM Moneta MV Zhu G Yue L Hong J Dueñas H Brugnoli R
author_sort	Novick D
title	Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
title_short	Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
title_full	Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
title_fullStr	Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
title_full_unstemmed	Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
title_sort	functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in east asia
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/817d96775c9744fba77c329c4524847d
work_keys_str_mv	AT novickd functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT montgomeryw functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT harojm functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT monetamv functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT zhug functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT yuel functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT hongj functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT duenash functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia AT brugnolir functioninginpatientswithmajordepressiontreatedwithduloxetineoraselectiveserotoninreuptakeinhibitorineastasia
_version_	1718402299051638784

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia

Ejemplares similares